What is Exenatide?
Exenatide is a GLP-1 receptor agonist originally derived from the saliva of the Gila monster lizard. FDA-approved as Byetta (twice daily) and Bydureon (once weekly) for type 2 diabetes. It was the first commercially available GLP-1 receptor agonist and paved the way for the entire drug class.
Key Benefits & Mechanisms
First-in-class GLP-1 agonist
FDA-approved for type 2 diabetes
Weight loss (modest)
Improved glycemic control
Once-weekly formulation available
Cardiovascular neutral (EXSCEL trial)
Well-established safety profile
Research Summary
Exenatide has extensive clinical evidence from multiple Phase III programs. FDA-approved since 2005. EXSCEL cardiovascular outcomes trial showed non-inferiority. While newer GLP-1 agents have surpassed it for weight loss, it remains an important therapeutic option with a long safety track record.